Essink BJ, Vermeulen W, Andrade C, de Rooij R, et al. A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older. Vaccine 2025;51:126791.
PMID: 39946829